Leoni, the leading European provider of cables and cable systems to the automotive sector and other industries like the healthcare branch, and IBA (Ion Beam Applications S.A.) have announced the availability of a newly advanced patient positioning system configuration from IBA, integrating the Leoni Orion System, a 6-degrees of freedom robot. The Leoni Orion System has been recently granted CE Mark, and is under 510(k) premarket review process by the FDA.
The Leoni Orion System has key advantages in optimized safety for both patients and radiotherapy staff.
The Leoni Orion System has key advantages in optimized safety for both patients and radiotherapy staff. It also improves the throughput of patients, thereby increasing the IBA cancer center’s efficiency. Additionally, the Leoni Orion System makes automated positioning adjustments possible in 6-degrees of freedom, to optimize a tumor’s location under the precise IBA proton treatment beam.
The Leoni Orion System is works with IBA’s compact single-room Proteus ONE and with IBA’s multi-room ProteusPLUS proton therapy solutions. Intuition and innovation in software and hardware The Leoni Orion System fulfills medical needs, combining an intuitive software solution with innovative hardware components, thus creating an unprecedented new standard in radiotherapy treatment. It provides multiple benefits, all targeting quick and precise treatment: the system offers several features to decrease the per patient treatment cycle time such as the possibility of preparing the patient outside the treatment room. It provides a dynamic positioning control in six degrees of freedom with sub-millimeter accuracy.
Moreover, the unit features a high patient-weight capacity in a large treatment volume. In addition, it installs quickly and easily in new and existing radiotherapy centers. Finally, it is flexible and easy to use, which allows clinical staffs to provide the greatest level of patient care. Strengthening IBA’s world leading position in proton therapy Gery Gevers, IBA’s Vice President of Research and Development: “IBA is committed to supporting the research efforts of its multiple partners towards even better treatment deliveries.
Proton therapy is a highly precise, targeted cancer radiotherapy treatment. Compared to photons, protons (relatively heavy subatomic particles) deposit most of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. The technique offer cancer centers the opportunity to develop new protocols delivering higher doses to the tumor aiming at improved outcome for risk of side-effects, or keeping the same dose but targeting improved patient’s quality of life.
